BRAF Antikörper

Produktnummer ABIN7880047

Der Maus Monoklonal anti-BRAF Antikörper (Klon BRAF-1626) (ABIN7880047) detektiert spezifisch BRAF in IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für BRAF Antikörper (ABIN7880047)

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BRAF Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: BRAF-1626

Produktdetails anti-BRAF Antikörper

Verwendungszweck: BRAF Antibody (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant fragment of human HMG20B/BRAF protein was used as the immunogen for the BRAF antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the BRAF antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the BRAF antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Andere Bezeichnung: BRAF

Hintergrund: The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia, 54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytoses and 60 % of pleomorphic xanthoastrocytomas.

UniProt: Q9P0W2

Pathways: MAPK Signalweg, RTK Signalweg, Neurotrophin Signalübertragung, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagie